8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
Stoke Therapeutics, Inc.(STOK)Earnings, Financials & Key Ratios
STOK•NASDAQ
$33.28
$1.96B mkt cap·Price updated May 6, 2026
AboutStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Show more
- Revenue$184M+404.5%
- EBITDA-$19M+81.0%
- Net Income-$7M+92.3%
- EPS (Diluted)-0.12+92.7%
- Gross Margin100%
- EBITDA Margin-10.21%+96.2%
- Operating Margin-11.16%+96.0%
- Net Margin-3.73%+98.5%
- ROE-2.37%+94.8%
- ROIC-8.31%+96.0%
- Interest Coverage-1.50
STOK Key Insights
Stoke Therapeutics, Inc. (STOK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 24.4% free cash flow margin
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
STOK Price & Volume
Stoke Therapeutics, Inc. (STOK) stock price & volume — 10-year historical chart
Loading chart...
STOK Growth Metrics
Stoke Therapeutics, Inc. (STOK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years145.89%
TTM404.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.67%
Return on Capital
10 Years-32.03%
5 Years-37.84%
3 Years-36.19%
Last Year-6.96%
STOK Recent Earnings
Stoke Therapeutics, Inc. (STOK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Mar 17, 2026EPS
$0.99
Est $0.92
-8.1%
Revenue
$1M
Est $6M
-77.5%
Q2 2026
Mar 16, 2026EPS
$0.97
Est $0.75
-29.3%
Revenue
$1M
Est $6M
-76.0%
Q4 2025
Nov 4, 2025EPS
$0.65
Est $0.54
-20.4%
Revenue
$11M
Est $5M
+133.4%
Q3 2025
Aug 12, 2025EPS
$0.40
Est $0.57
+29.8%
Revenue
$14M
Est $5M
+158.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 17, 2026 | $0.99vs $0.92-8.1% | $1Mvs $6M-77.5% |
| Q2 2026 | Mar 16, 2026 | $0.97vs $0.75-29.3% | $1Mvs $6M-76.0% |
| Q4 2025 | Nov 4, 2025 | $0.65vs $0.54-20.4% | $11Mvs $5M+133.4% |
| Q3 2025 | Aug 12, 2025 | $0.40vs $0.57+29.8% | $14Mvs $5M+158.0% |
Based on last 12 quarters of dataView full earnings history →
STOK Peer Comparison
Stoke Therapeutics, Inc. (STOK) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 |
Compare STOK vs Peers
Stoke Therapeutics, Inc. (STOK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STOK Income Statement
Stoke Therapeutics, Inc. (STOK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 12.4M | 8.78M | 36.55M | 184.42M |
| Revenue Growth % | - | - | - | - | - | - | -29.22% | 316.34% | 404.5% |
| Cost of Goods Sold | 113K | 214K | 450K | 1.93M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -113K▲ 0% | -214K▼ 89.4% | -450K▼ 110.3% | -1.93M▼ 328.0% | 0▲ 100.0% | 12.4M▲ 0% | 8.78M▼ 29.2% | 36.55M▲ 316.3% | 184.42M▲ 404.5% |
| Gross Margin % | - | - | - | - | - | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | -89.38% | -110.28% | -328% | 100% | - | -29.22% | 316.34% | 404.5% |
| Operating Expenses | 5.55M | 12.78M | 35.23M | 51.12M | 86.06M | 116.76M | 123.55M | 137.93M | 205.01M |
| OpEx % of Revenue | - | - | - | - | - | 941.24% | 1407.21% | 377.31% | 111.16% |
| Selling, General & Admin | 1.96M | 4.41M | 11.91M | 20.85M | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| SG&A % of Revenue | - | - | - | - | - | 313.78% | 470.64% | 133.48% | 36.38% |
| Research & Development | 3.6M | 8.37M | 23.31M | 32.2M | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| R&D % of Revenue | - | - | - | - | - | 627.46% | 936.57% | 243.83% | 74.79% |
| Other Operating Expenses | -4K | -10K | 0 | -1.93M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.55M▲ 0% | -12.78M▼ 130.1% | -35.68M▼ 179.1% | -53.04M▼ 48.7% | -86.06M▼ 62.3% | -104.36M▼ 21.3% | -114.77M▼ 10.0% | -101.37M▲ 11.7% | -20.59M▲ 79.7% |
| Operating Margin % | - | - | - | - | - | -841.24% | -1307.21% | -277.31% | -11.16% |
| Operating Income Growth % | - | -130.12% | -179.15% | -48.67% | -62.25% | -21.25% | -9.98% | 11.68% | 79.69% |
| EBITDA | -5.44M | -12.57M | -35.23M | -51.12M | -85.09M | -102.81M | -112.3M | -99.19M | -18.82M |
| EBITDA Margin % | - | - | - | - | - | -828.78% | -1279.09% | -271.36% | -10.21% |
| EBITDA Growth % | - | -130.97% | -180.32% | -45.11% | -66.46% | -20.82% | -9.23% | 11.67% | 81.03% |
| D&A (Non-Cash Add-back) | 113K | 214K | 450K | 1.93M | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBIT | -5.55M | -12.78M | -32.33M | -52.24M | -86.06M | -104.36M | -114.77M | -101.37M | -20.59M |
| Net Interest Income | 0 | 0 | 3.35M | 744K | 120K | 0 | 0 | 0 | -13.76M |
| Interest Income | 0 | 270K | 3.35M | 744K | 120K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.76M |
| Other Income/Expense | -4K | 260K | 3.35M | 801K | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Pretax Income | -5.56M▲ 0% | -12.52M▼ 125.3% | -32.33M▼ 158.2% | -52.24M▼ 61.6% | -85.81M▼ 64.2% | -101.07M▼ 17.8% | -104.7M▼ 3.6% | -88.98M▲ 15.0% | -6.88M▲ 92.3% |
| Pretax Margin % | - | - | - | - | - | -814.73% | -1192.47% | -243.42% | -3.73% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.56M▲ 0% | -12.52M▼ 125.3% | -32.33M▼ 158.2% | -52.24M▼ 61.6% | -85.81M▼ 64.2% | -101.07M▼ 17.8% | -104.7M▼ 3.6% | -88.98M▲ 15.0% | -6.88M▲ 92.3% |
| Net Margin % | - | - | - | - | - | -814.73% | -1192.47% | -243.42% | -3.73% |
| Net Income Growth % | - | -125.28% | -158.17% | -61.62% | -64.24% | -17.79% | -3.59% | 15.01% | 92.26% |
| Net Income (Continuing) | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M | -6.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24▲ 0% | -0.53▼ 120.8% | -1.59▼ 200.0% | -1.56▲ 1.9% | -2.34▼ 50.0% | -2.60▼ 11.1% | -2.38▲ 8.5% | -1.65▲ 30.7% | -0.12▲ 92.7% |
| EPS Growth % | - | -120.83% | -200% | 1.89% | -50% | -11.11% | 8.46% | 30.67% | 92.73% |
| EPS (Basic) | -0.24 | -0.53 | -1.59 | -1.56 | -2.34 | -2.60 | -2.38 | -1.65 | -0.12 |
| Diluted Shares Outstanding | 23.51M | 23.51M | 17.97M | 33.49M | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Basic Shares Outstanding | 23.51M | 23.51M | 17.97M | 33.49M | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
STOK Balance Sheet
Stoke Therapeutics, Inc. (STOK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.91M | 106.14M | 226.03M | 293.93M | 229.22M | 244.07M | 215.34M | 232.76M | 305.7M |
| Cash & Short-Term Investments | 1.8M | 105.4M | 222.47M | 287.31M | 219.81M | 229.59M | 201.39M | 216.9M | 284.67M |
| Cash Only | 1.8M | 105.4M | 222.47M | 287.31M | 144.9M | 113.56M | 191.44M | 127.98M | 84.22M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 74.92M | 116.04M | 9.95M | 88.92M | 200.45M |
| Accounts Receivable | 0 | 196K | 281K | 6K | 132K | 588K | 64K | 700K | 7.91M |
| Days Sales Outstanding | - | - | - | - | - | 17.3 | 2.66 | 6.99 | 15.65 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 181K | 2.33M | 2.96M | 2.56M | 4.04M | 13.13M |
| Total Non-Current Assets | 529K | 1.4M | 2.72M | 4M | 9.65M | 12M | 13M | 38.8M | 112.73M |
| Property, Plant & Equipment | 473K | 1.19M | 2.51M | 3.79M | 9.08M | 11.43M | 12.43M | 8.25M | 6.25M |
| Fixed Asset Turnover | - | - | - | - | - | 1.09x | 0.71x | 4.43x | 29.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 56K | 204K | 0 | 0 | 0 | 0 | 0 | 29.82M | 0 |
| Other Non-Current Assets | 0 | 0 | 205K | 205K | 569K | 569K | 569K | 721K | 106.49M |
| Total Assets | 2.44M▲ 0% | 107.54M▲ 4309.1% | 228.75M▲ 112.7% | 297.93M▲ 30.2% | 238.87M▼ 19.8% | 256.07M▲ 7.2% | 228.34M▼ 10.8% | 271.56M▲ 18.9% | 418.43M▲ 54.1% |
| Asset Turnover | - | - | - | - | - | 0.05x | 0.04x | 0.13x | 0.44x |
| Asset Growth % | - | 4309.14% | 112.71% | 30.24% | -19.82% | 7.2% | -10.83% | 18.92% | 54.09% |
| Total Current Liabilities | 3.71M | 2.47M | 4.1M | 11.43M | 17.14M | 31.39M | 30.82M | 40.06M | 57.88M |
| Accounts Payable | 141K | 1.07M | 751K | 1.5M | 2.38M | 766K | 1.7M | 2.5M | 4.94M |
| Days Payables Outstanding | 455.44 | 1.83K | 609.14 | 283.32 | - | - | - | - | - |
| Short-Term Debt | 3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -3M | 0 | 0 | 0 | 0 | 14.88M | 15.31M | 18.99M | 11.9M |
| Other Current Liabilities | 0 | 0 | 2.11M | 4.58M | 5.92M | 6.26M | 6.47M | 8.44M | 41.03M |
| Current Ratio | 0.51x | 43.03x | 55.12x | 25.73x | 13.37x | 7.77x | 6.99x | 5.81x | 5.28x |
| Quick Ratio | 0.51x | 43.03x | 55.12x | 25.73x | 13.37x | 7.77x | 6.99x | 5.81x | 5.28x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 16K | 4K | 221K | 422K | 3.95M | 39.82M | 37.96M | 2.48M | 8.1M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 16K | 4K | 221K | 422K | 3.95M | 2.97M | 4.88M | 2.48M | 8.1M |
| Total Liabilities | 3.73M | 2.47M | 4.32M | 11.85M | 21.09M | 71.22M | 68.78M | 42.53M | 65.98M |
| Total Debt | 3M | 0 | 0 | 1.07M | 1.51M | 2.36M | 2.06M | 2.32M | 0 |
| Net Debt | 1.2M | -105.4M | -222.47M | -286.24M | -143.39M | -111.2M | -189.38M | -125.66M | -84.22M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -1.50x |
| Total Equity | -1.29M▲ 0% | 105.07M▲ 8232.2% | 224.43M▲ 113.6% | 286.08M▲ 27.5% | 217.78M▼ 23.9% | 184.85M▼ 15.1% | 159.56M▼ 13.7% | 229.02M▲ 43.5% | 352.46M▲ 53.9% |
| Equity Growth % | - | 8232.2% | 113.6% | 27.47% | -23.88% | -15.12% | -13.68% | 43.53% | 53.9% |
| Book Value per Share | -0.05 | 4.47 | 12.49 | 8.54 | 5.93 | 4.75 | 3.63 | 4.24 | 5.95 |
| Total Shareholders' Equity | -1.29M | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | 159.56M | 229.02M | 352.46M |
| Common Stock | 1K | 1K | 3K | 4K | 4K | 4K | 5K | 5K | 5K |
| Retained Earnings | -13.19M | -25.71M | -58.03M | -110.28M | -196.08M | -297.15M | -401.85M | -490.83M | -497.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -172K | -379K | 0 | 0 | -168K | -1.18M | -24K | -151K | 543K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STOK Cash Flow Statement
Stoke Therapeutics, Inc. (STOK) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.38M | -10.96M | -31.05M | -42.22M | -66.91M | -31.87M | -81.07M | -86.85M | 45.59M |
| Operating CF Margin % | - | - | - | - | - | -256.88% | -923.31% | -237.59% | 24.72% |
| Operating CF Growth % | - | -103.64% | -183.25% | -35.96% | -58.47% | 52.37% | -154.4% | -7.13% | 152.49% |
| Net Income | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M | -6.88M |
| Depreciation & Amortization | 113K | 214K | 450K | 888K | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| Stock-Based Compensation | 26K | 240K | 1.92M | 5.77M | 16.45M | 22.85M | 25.26M | 27.47M | 32.24M |
| Deferred Taxes | 0 | 0 | 0 | 3K | 172K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4K | 10K | 3K | 1.04M | 1.26M | 1.78M | 1.94M | 623K | 2.12M |
| Working Capital Changes | 31K | 1.09M | -1.1M | 2.33M | 46K | 43.02M | -6.03M | -28.14M | 16.35M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.27M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 100K | 1.74M | 891K | 5.2M | 2.9M | 121K | -3.21M | 3.09M | 21.29M |
| Cash from Investing | -113K | -925K | -1.63M | -1.05M | -76.43M | -45.88M | 105.95M | -107.47M | -186.81M |
| Capital Expenditures | -113K | -935K | -1.64M | -1.05M | -1.2M | -3.96M | -1.62M | -203K | -670K |
| CapEx % of Revenue | - | - | - | - | - | 31.94% | 18.41% | 0.56% | 0.36% |
| Acquisitions | 0 | 10K | 1K | 0 | 75.23M | 45.34M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 10K | 0 | 0 | -75.23M | -45.34M | 0 | 0 | 0 |
| Cash from Financing | 5.97M | 115.64M | 149.76M | 108.11M | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.97M | -361K | -2.15M | 2.71M | -2K | 1.06M | 926K | 2.25M | 0 |
| Net Change in Cash | 477K▲ 0% | 103.75M▲ 21650.5% | 117.07M▲ 12.8% | 64.84M▼ 44.6% | -142.05M▼ 319.1% | -31.34M▲ 77.9% | 77.89M▲ 348.5% | -63.23M▼ 181.2% | -43.84M▲ 30.7% |
| Free Cash Flow | -5.5M▲ 0% | -11.9M▼ 116.5% | -32.69M▼ 174.7% | -43.27M▼ 32.4% | -68.11M▼ 57.4% | -35.83M▲ 47.4% | -82.68M▼ 130.8% | -87.05M▼ 5.3% | 44.91M▲ 151.6% |
| FCF Margin % | - | - | - | - | - | -288.82% | -941.72% | -238.15% | 24.35% |
| FCF Growth % | - | -116.46% | -174.73% | -32.37% | -57.4% | 47.39% | -130.78% | -5.29% | 151.59% |
| FCF per Share | -0.23 | -0.51 | -1.82 | -1.29 | -1.85 | -0.92 | -1.88 | -1.61 | 0.76 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.88x | 0.96x | 0.81x | 0.78x | 0.32x | 0.77x | 0.98x | -6.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STOK Key Ratios
Stoke Therapeutics, Inc. (STOK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -24.13% | -19.62% | -20.47% | -34.06% | -50.2% | -60.8% | -45.8% | -2.37% |
| Return on Invested Capital (ROIC) | - | - | -3291.33% | -4437.59% | -173.93% | -105.74% | -392.73% | -206.76% | -8.31% |
| Gross Margin | - | - | - | - | - | 100% | 100% | 100% | 100% |
| Net Margin | - | - | - | - | - | -814.73% | -1192.47% | -243.42% | -3.73% |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -1.50x |
| FCF Conversion | 0.97x | 0.88x | 0.96x | 0.81x | 0.78x | 0.32x | 0.77x | 0.98x | -6.62x |
| Revenue Growth | - | - | - | - | - | - | -29.22% | 316.34% | 404.5% |
STOK SEC Filings & Documents
Stoke Therapeutics, Inc. (STOK) SEC filings — annual & quarterly reports (10-K, 10-Q)
STOK Frequently Asked Questions
Stoke Therapeutics, Inc. (STOK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Stoke Therapeutics, Inc. (STOK) reported $184.4M in revenue for fiscal year 2025.
Stoke Therapeutics, Inc. (STOK) grew revenue by 404.5% over the past year. This is strong growth.
Stoke Therapeutics, Inc. (STOK) reported a net loss of $6.9M for fiscal year 2025.
Dividend & Returns
Stoke Therapeutics, Inc. (STOK) has a return on equity (ROE) of -2.4%. Negative ROE indicates the company is unprofitable.
Stoke Therapeutics, Inc. (STOK) generated $44.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More STOK
Stoke Therapeutics, Inc. (STOK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates